SAGE Sage Therapeutics Inc

Price (delayed)

$46.4

Market cap

$2.73B

P/E Ratio

3.5

Dividend/share

N/A

EPS

$13.26

Enterprise value

$2.23B

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing ...

Highlights
The company's debt fell by 32% YoY and by 6% QoQ
SAGE's gross margin is up by 8% YoY
SAGE's equity has soared by 161% YoY but it is down by 3.7% from the previous quarter
SAGE's quick ratio has soared by 131% YoY but it is down by 17% QoQ

Key stats

What are the main financial stats of SAGE
Market
Shares outstanding
58.81M
Market cap
$2.73B
Enterprise value
$2.23B
Valuations
Price to earnings (P/E)
3.5
Price to book (P/B)
1.41
Price to sales (P/S)
2.44
EV/EBIT
3.35
EV/EBITDA
3.33
EV/Sales
2.01
Earnings
Revenue
$1.11B
EBIT
$666.15M
EBITDA
$670.93M
Free cash flow
$708.1M
Per share
EPS
$13.26
Free cash flow per share
$12.09
Book value per share
$32.99
Revenue per share
$19.02
TBVPS
$34.4
Balance sheet
Total assets
$2.02B
Total liabilities
$85.96M
Debt
$21.32M
Equity
$1.93B
Working capital
$1.92B
Liquidity
Debt to equity
0.01
Current ratio
27.66
Quick ratio
27.28
Net debt/EBITDA
-0.74
Margins
EBITDA margin
60.2%
Gross margin
99.9%
Net margin
59.8%
Operating margin
59.4%
Efficiency
Return on assets
38.1%
Return on equity
40%
Return on invested capital
74.6%
Return on capital employed
34.3%
Return on sales
59.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SAGE stock price

How has the Sage Therapeutics stock price performed over time
Intraday
2.43%
1 week
2.68%
1 month
8.56%
1 year
-22.8%
YTD
-46.36%
QTD
-18.32%

Financial performance

How have Sage Therapeutics's revenue and profit performed over time
Revenue
$1.11B
Gross profit
$1.11B
Operating income
$662.29M
Net income
$666.15M
Gross margin
99.9%
Net margin
59.8%
Sage Therapeutics's operating margin has surged by 101% YoY and by 4.8% QoQ
The company's net margin has surged by 101% YoY and by 4.5% QoQ
SAGE's gross margin is up by 8% YoY
Sage Therapeutics's operating income has increased by 4.9% from the previous quarter

Growth

What is Sage Therapeutics's growth rate over time

Valuation

What is Sage Therapeutics stock price valuation
P/E
3.5
P/B
1.41
P/S
2.44
EV/EBIT
3.35
EV/EBITDA
3.33
EV/Sales
2.01
Sage Therapeutics's EPS has increased by 6% from the previous quarter
SAGE's equity has soared by 161% YoY but it is down by 3.7% from the previous quarter
The P/B is 76% less than the 5-year quarterly average of 5.9 and 48% less than the last 4 quarters average of 2.7
SAGE's P/S is 98% below its last 4 quarters average of 116.6

Efficiency

How efficient is Sage Therapeutics business performance
The ROIC has soared by 192% YoY but it has contracted by 22% from the previous quarter
SAGE's ROA has soared by 163% year-on-year but it is down by 13% since the previous quarter
Sage Therapeutics's ROE has soared by 159% YoY but it has decreased by 14% from the previous quarter
Sage Therapeutics's ROS has soared by 101% YoY and by 4.5% from the previous quarter

Dividends

What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SAGE.

Financial health

How did Sage Therapeutics financials performed over time
The total assets has surged by 144% year-on-year but it has declined by 3.1% since the previous quarter
SAGE's quick ratio has soared by 131% YoY but it is down by 17% QoQ
The company's debt is 99% lower than its equity
SAGE's equity has soared by 161% YoY but it is down by 3.7% from the previous quarter
The debt to equity has plunged by 75% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.